ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. **NAME OF THE MEDICINAL PRODUCT**

QUVIVIQ 25 mg film-coated tablets
QUVIVIQ 50 mg film-coated tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

**QUVIVIQ 25 mg film-coated tablets**
Each film-coated tablet contains daridorexant hydrochloride equivalent to 25 mg of daridorexant.

**QUVIVIQ 50 mg film-coated tablets**
Each film-coated tablet contains daridorexant hydrochloride equivalent to 50 mg of daridorexant.

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Film-coated tablet (tablet).

**QUVIVIQ 25 mg film-coated tablets**
Light purple arc-triangle shaped film-coated tablets, debossed with ‘25’ on one side, and ‘i’ on the other side.

**QUVIVIQ 50 mg film-coated tablets**
Light orange arc-triangle shaped film-coated tablets, debossed with ‘50’ on one side, and ‘i’ on the other side.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

QUVIVIQ is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

4.2 **Posology and method of administration**

**Posology**

The recommended dose for adults is one tablet of 50 mg once per night, taken orally in the evening within 30 minutes before going to bed. Based on clinical judgement, some patients may be treated with 25 mg once per night (see sections 4.4 and 4.5).

The maximum daily dose is 50 mg.
The treatment duration should be as short as possible. The appropriateness of continued treatment should be assessed within 3 months and periodically thereafter. Clinical data are available for up to 12 months of continuous treatment.

Treatment can be stopped without down-titration.

Missed dose
If a patient forgets to take QUVIVIQ at bedtime, that dose should not be taken during the night.

Hepatic impairment
In patients with mild hepatic impairment, no dose adjustment is required. In patients with moderate hepatic impairment, the recommended dose is one tablet of 25 mg once per night (see section 5.2). In patients with severe hepatic impairment, daridorexant has not been studied and is not recommended (see section 4.4).

Renal impairment
In patients with renal impairment (including severe), no dose adjustment is required (see section 5.2).

Co-administration with moderate CYP3A4 inhibitors
The recommended dose when used with moderate CYP3A4 inhibitors is one tablet of 25 mg once per night (see section 4.5).

The consumption of grapefruit or grapefruit juice in the evening should be avoided.

Co-administration with central nervous system (CNS) depressants
In the case of co-administration with CNS-depressant medicinal products, dose adjustments of QUVIVIQ and/or the other medicinal products may be required, based on clinical evaluation, due to potentially additive effects (see sections 4.4 and 4.5).

Elderly
No dose adjustment is required in elderly patients (> 65 years). Limited data are available in patients older than 75 years. No data are available in patients older than 85 years.

Paediatric population
The safety and efficacy of daridorexant in paediatric patients have not yet been established. No data are available.

Method of administration
For oral use.

QUVIVIQ can be taken with or without food. However, taking QUVIVIQ soon after a large meal may reduce the effect on sleep onset (see section 5.2).

4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Narcolepsy.
- Concomitant use with strong CYP3A4 inhibitors (see section 4.5).
4.4 Special warnings and precautions for use

Elderly

Because of the general risk of falls in the elderly, daridorexant should be used with caution in this population, although clinical studies did not show an increase in the incidence of falls on daridorexant compared to placebo.

QUVIVIQ should be administered with caution in patients older than 75 years since efficacy and safety data in this population are limited.

CNS-depressant effects

Because daridorexant acts by reducing wakefulness, patients should be cautioned about engaging in potentially hazardous activities, driving, or operating heavy machinery unless they feel fully alert, especially in the first few days of treatment (see section 4.7).

Caution should be exercised when prescribing QUVIVIQ concomitantly with CNS-depressant medicinal products due to potentially additive effects, and a dose adjustment of either QUVIVIQ or the concomitant CNS depressants should be considered.

Patients should be cautioned about drinking alcohol during treatment with QUVIVIQ (see section 4.5).

Sleep paralysis, hallucinations and cataplexy-like symptoms

Sleep paralysis, an inability to move or speak for up to several minutes during sleep-wake transitions, and hypnagogic/hypnopompic hallucinations, including vivid and disturbing perceptions, can occur with daridorexant, mainly during the first weeks of treatment (see section 4.8).

Symptoms similar to mild cataplexy have been reported with dual orexin receptor antagonists.

Prescribers should explain the nature of these events to patients when prescribing QUVIVIQ. Should such events occur, patients need to be further evaluated and, depending on the nature and severity of the events, discontinuation of treatment should be considered.

Worsening of depression and suicidal ideation

In primarily depressed patients treated with hypnotics, worsening of depression and suicidal thoughts and actions have been reported. As with other hypnotics, QUVIVIQ should be administered with caution in patients exhibiting symptoms of depression.

Isolated cases of suicidal ideation have been reported in Phase 3 clinical studies, in subjects with pre-existing psychiatric conditions and/or stressful living conditions, across all treatment groups, including placebo. Suicidal tendencies may be present in patients with depression and protective measures may be required.

Patients with psychiatric co-morbidities

QUVIVIQ should be administered with caution in patients with psychiatric co-morbidities since efficacy and safety data in this patient population are limited.

Patients with compromised respiratory function

Daridorexant did not increase the frequency of apnoea/hypopnoea events or cause oxygen desaturation in patients with mild or moderate obstructive sleep apnoea (OSA), nor did it cause oxygen
desaturation in patients with moderate chronic obstructive pulmonary disease (COPD). Daridorexant has not been studied in patients with severe OSA (apnoea-hypopnoea index ≥ 30 events per hour) or with severe COPD (FEV1 < 40% of predicted).

Caution should be exercised when prescribing QUVIVIQ to patients with severe OSA and severe COPD.

Potential for abuse and dependence

There was no evidence of abuse or withdrawal symptoms indicative of physical dependence upon treatment discontinuation in clinical studies with daridorexant in subjects with insomnia.

In an abuse liability study of daridorexant (50, 100 and 150 mg) conducted in non-insomniac recreational drug users (n = 72), daridorexant (100 and 150 mg) produced similar “drug liking” ratings as zolpidem (30 mg). Because individuals with a history of abuse or addiction to alcohol or other substances may be at increased risk for abuse of QUVIVIQ, these patients should be followed carefully.

Hepatic impairment

Use is not recommended in patients with severe hepatic impairment (see sections 4.2 and 5.2).

Excipients

Sodium
This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

4.5 Interaction with other medicinal products and other forms of interaction

Effect of other medicinal products on the pharmacokinetics of daridorexant

CYP3A4 inhibitors
In healthy subjects, co-administration of daridorexant 25 mg with the moderate CYP3A4 inhibitor diltiazem (240 mg once daily) increased daridorexant exposure parameters AUC and Cmax by 2.4 times and 1.4 times, respectively. In patients taking moderate CYP3A4 inhibitors (e.g., erythromycin, ciprofloxacin, cyclosporine), the recommended dose of QUVIVIQ is 25 mg.

No clinical study was conducted with a strong CYP3A4 inhibitor. Concomitant use of QUVIVIQ with strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, ritonavir) is contraindicated (see section 4.3).

The consumption of grapefruit or grapefruit juice in the evening should be avoided.

CYP3A4 inducers
In healthy subjects, co-administration with efavirenz (600 mg once daily), a moderate CYP3A4 inducer, decreased daridorexant exposure parameters AUC and Cmax by 61% and 35%, respectively.

Based on these results, concomitant use with a moderate or strong CYP3A4 inducer substantially decreases exposure to daridorexant, which may reduce efficacy.

Gastric pH-modifiers
The solubility of daridorexant is pH-dependent. In healthy subjects, co-administration with famotidine (40 mg), an inhibitor of gastric acid secretion, decreased daridorexant Cmax by 39% while AUC remained unchanged.
No dose adjustment is required when QUVIVIQ is used concomitantly with treatments that reduce gastric acidity.

Citalopram
In healthy subjects, co-administration of 20 mg citalopram, a selective serotonin re-uptake inhibitor (SSRI), did not have any clinically relevant effect on the PK of 50 mg daridorexant.

Effect of daridorexant on the pharmacokinetics of other medicinal products

Substrates of CYP3A4
In a clinical study conducted in healthy subjects receiving daridorexant and midazolam, a sensitive CYP3A4 substrate, daridorexant at a dose of 25 mg did not affect the PK of midazolam, indicating an absence of CYP3A4 induction or inhibition. QUVIVIQ can be administered with CYP3A4 substrates (e.g., simvastatin, ticagrelor) without dose adjustment.

Based on in vitro results (see section 5.2), daridorexant inhibited and induced CYP3A4. In the absence of clinical data with 50 mg, caution should be used in case of concomitant administration with CYP3A4 substrates, including oral contraceptives, with close safety and efficacy monitoring in case of medicinal products with a narrow therapeutic index that cannot be avoided.

Substrates of CYP2C9
Based on in vitro results (see section 5.2), daridorexant induced CYP2C9. In the absence of clinical data, caution should be used in case of concomitant administration with CYP2C9 substrates with close efficacy monitoring in case of medicinal products with a narrow therapeutic index.

Substrates of BCRP or P-gp transporters
In a clinical study conducted in healthy subjects receiving daridorexant 25 mg and rosuvastatin, a BCRP substrate, daridorexant did not affect the PK of rosuvastatin, indicating an absence of inhibition of BCRP. In the absence of clinical data at 50 mg, simultaneous administration of QUVIVIQ with BCRP substrates (e.g., rosuvastatin, imatinib) should be handled with caution.

Based on in vitro studies (see section 5.2), daridorexant is an inhibitor of several transporters, including P-gp, with the strongest inhibition seen on BCRP. In the absence of clinical data, simultaneous administration of QUVIVIQ with P-gp substrates (e.g., digoxin, dabigatran) should be handled with caution, with close monitoring in case of medicinal products with a narrow therapeutic index (e.g., digoxin).

Alcohol
In healthy subjects, concomitant intake with alcohol led to a prolonged absorption of daridorexant ($t_{max}$ increased by 1.25 h). Daridorexant exposure ($C_{max}$ and AUC) and $t_{1/2}$ were unchanged.

Citalopram
In healthy subjects, the PK of citalopram at steady state was not affected by co-administration of 50 mg daridorexant.

Pharmacodynamic interactions

Alcohol
Co-administration of 50 mg daridorexant with alcohol led to additive effects on psychomotor performance.

Citalopram
No relevant interaction on psychomotor performance was observed when 50 mg daridorexant was co-administered with 20 mg citalopram in healthy subjects at steady state.
Paediatric population

Interaction studies have only been performed in adults.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no data on the use of daridorexant in pregnant women. Animal studies did not indicate harmful effects with respect to reproductive toxicity (see section 5.3).

Consequently, QUVIVIQ should be used during pregnancy only if the clinical condition of the pregnant woman requires treatment with daridorexant.

Breast-feeding

It is unknown whether daridorexant or its metabolites are excreted in human milk. Available data in animals have shown excretion of daridorexant and its metabolites in milk (see section 5.3).

A risk of excessive somnolence to the breastfed infant cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from QUVIVIQ therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility

There are no data concerning the effect of exposure to daridorexant on human fertility. Animal studies indicate no impact on male or female fertility (see section 5.3).

4.7 Effects on ability to drive and use machines

Hypnotics have a major influence on the ability to drive and use machines.

A randomised, double-blind, placebo- and active-controlled, cross-over study evaluated the effects of nighttime administration of daridorexant on next-morning driving performance, using a driving simulator, 9 hours after dosing in non-insomniac, healthy subjects aged from 50 to 79 years. Testing was conducted after 1 night (initial dosing) and after 4 consecutive nights of treatment with daridorexant 50 mg. Zopiclone 7.5 mg was used as an active comparator.

In the morning after first-dose administration, daridorexant impaired simulated driving performance as measured by the Standard Deviation of the Lateral Position (SDLP). No effect on driving performance was detected after 4 consecutive nights of treatment with daridorexant 50 mg. Zopiclone significantly impaired simulated driving performance at both time points.

Patients should be cautioned about engaging in potentially hazardous activities, driving, or operating heavy machinery unless they feel fully alert, especially in the first few days of treatment (see section 4.4). In order to minimise this risk, a period of approximately 9 hours is recommended between taking QUVIVIQ and driving or using machines.

4.8 Undesirable effects

Summary of safety profile

The most frequently reported adverse reactions were headache and somnolence.
The majority of adverse reactions were mild to moderate in intensity. No evidence of a dose-
relationship for the frequency or severity of adverse reactions was observed. The adverse reaction 
profile in elderly subjects was consistent with younger subjects.

**Tabulated list of adverse reactions**

Table 1 shows adverse reactions that occurred in Study 1 and Study 2.

The frequency of adverse reactions is defined using the following convention: very common (≥ 1/10); 
common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very 
rare (< 1/10,000); not known (cannot be estimated from the available data). Within each frequency 
grouping, adverse reactions are presented in order of decreasing seriousness.

The safety of daridorexant was evaluated in three placebo-controlled Phase 3 clinical studies. A total 
of 1847 subjects (including approximately 40% elderly subjects [≥ 65 years old]) received 
daridorexant 50 mg (N = 308); 25 mg (N = 618); or 10 mg (N = 306), or placebo (N = 615). A total of 
576 subjects were treated with daridorexant for at least 6 months and 331 for at least 12 months.

**Table 1: Adverse reactions**

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Adverse reaction</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychiatric disorders</td>
<td>Hallucination</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Headache</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Somnolence</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td>Sleep paralysis</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Nausea</td>
<td>Common</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Fatigue</td>
<td>Common</td>
</tr>
</tbody>
</table>

**Description of selected adverse reactions**

**Somnolence**

Somnolence was reported in 3% and 2% of subjects treated with daridorexant 25 mg and 50 mg, 
respectively, compared to 2% of subjects on placebo.

**Sleep paralysis and hallucinations**

Sleep paralysis was reported in 0.5% and 0.3% subjects receiving daridorexant 25 mg and 50 mg, 
respectively, compared to no reports for placebo. Hypnagogic and hypnopompic hallucinations were 
reported in 0.6% subjects receiving daridorexant 25 mg compared to no cases with daridorexant 50 mg 
or placebo. Sleep paralysis and hallucinations occur mainly during the first weeks of treatment.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It 
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare 
professionals are asked to report any suspected adverse reactions via the national reporting system 
listed in Appendix V.

**4.9 Overdose**

In clinical pharmacology studies, healthy subjects were administered single doses of up to 200 mg 
daridorexant (4 times the recommended dose). At supra-therapeutic doses, adverse reactions of 
somnolence, muscular weakness, disturbance in attention, fatigue, headache, and constipation were 
observed.
There is no specific antidote to an overdose of daridorexant. In the event of an overdose, general symptomatic and supportive medical care should be provided and patients should be carefully monitored. Dialysis is unlikely to be effective as daridorexant is highly protein-bound.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: not yet assigned, ATC code: not yet assigned

**Mechanism of action**

Daridorexant is a dual orexin receptor antagonist, acting on both orexin 1 and orexin 2 receptors and equipotent on both. The orexin neuropeptides (orexin A and orexin B) act on orexin receptors to promote wakefulness. Daridorexant antagonises the activation of orexin receptors by the orexin neuropeptides and consequently decreases the wake drive, allowing sleep to occur, without altering the proportion of sleep stages (as assessed by electroencephalographic recording in rodents or polysomnography in patients with insomnia).

**Clinical efficacy and safety**

The efficacy of daridorexant was evaluated in two multicentre, randomised, double-blind, placebo-controlled, parallel-group, Phase 3 studies, Study 1 and Study 2, which were identical in design.

A total of 1854 subjects with insomnia disorder (dissatisfaction with sleep quantity or quality, for at least 3 months, with clinically significant distress or impairment in daytime functioning) were randomised to receive daridorexant or placebo once daily, in the evening, for 3 months. Study 1 randomised 930 subjects to daridorexant 50 mg (N = 310), 25 mg (N = 310), or placebo (N = 310). Study 2 randomised 924 subjects to daridorexant 25 mg (N = 309), 10 mg (N = 307), or placebo (N = 308). At baseline, the proportion of subjects with an Insomnia Severity Index (ISI) score between 8–14, 15–21, and 22–28, was 12%, 58%, and 30%, respectively.

At the end of the 3-month treatment period, both confirmatory studies included a 7-day placebo run-out period, after which subjects could enter a 9-month double-blind, placebo-controlled extension study (Study 3). A total of 576 subjects were treated with daridorexant for at least 6 months of cumulative treatment, including 331 treated for at least 12 months.

In Study 1, subjects had a mean age of 55.4 years (range 18 to 88 years), with 39.1% of subjects ≥ 65 years of age, including 5.8% ≥ 75 years of age. The majority were female (67.1%).

In Study 2, subjects had a mean age of 56.7 years (range 19 to 85 years), with 39.3% of subjects ≥ 65 years of age, including 6.1% ≥ 75 years of age. The majority were female (69.0%).

Primary efficacy endpoints for both studies were the change from baseline to Month 1 and Month 3 in Latency to Persistent Sleep (LPS) and Wake After Sleep Onset (WASO), measured objectively by polysomnography in a sleep laboratory. LPS is a measure of sleep induction and WASO is a measure of sleep maintenance.

Secondary endpoints included in the statistical testing hierarchy with Type 1 error control were patient-reported Total Sleep Time (sTST), evaluated every morning at home using a Sleep Diary Questionnaire (SDQ), and patient-reported daytime functioning, assessed using the sleepiness domain of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ), every evening at home. The IDSIQ total score, Alert/cognition, and Mood domain scores were also evaluated to complete the assessment of daytime functioning.
Effect of daridorexant on sleep and daytime functioning

Across the two studies, the efficacy of daridorexant increased with increasing dose on objective (LPS, WASO) and subjective (sTST) sleep variables as well as on daytime functioning as assessed by IDSIQ scores, both at Month 1 and Month 3.

In Study 1, the 50 mg dose showed statistically significant (p < 0.001) improvements compared to placebo on all primary and secondary endpoints. For the 25 mg dose, statistical significance was consistently achieved on WASO and sTST across both studies, and on LPS in Study 1. The 10 mg dose was not effective.

The efficacy of daridorexant was similar across subgroups based on age, sex, race and region.

Table 2: Efficacy on sleep variables and daytime functioning – Study 1

<table>
<thead>
<tr>
<th></th>
<th>50 mg (N = 310)</th>
<th>25 mg (N = 310)</th>
<th>Placebo (N = 310)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WASO (wake after sleep onset, min): sleep maintenance, assessed objectively by PSG</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline Mean (SD)</td>
<td>95 (38)</td>
<td>98 (39)</td>
<td>103 (41)</td>
</tr>
<tr>
<td>Month 1 Mean (SD)</td>
<td>65 (35)</td>
<td>77 (42)</td>
<td>92 (42)</td>
</tr>
<tr>
<td>Change from baseline LSM (95% CL)</td>
<td>-29 [-33, -25]</td>
<td>-18 [-22, -15]</td>
<td>-6 [-10, -2]</td>
</tr>
<tr>
<td>Difference to placebo LSM (95% CL)</td>
<td>-23 [-28, -18]</td>
<td>-12 [-17, -7]</td>
<td></td>
</tr>
<tr>
<td>Month 3 Mean (SD)</td>
<td>65 (39)</td>
<td>73 (40)</td>
<td>87 (43)</td>
</tr>
<tr>
<td>Change from baseline LSM (95% CL)</td>
<td>-29 [-33, -25]</td>
<td>-23 [-27, -19]</td>
<td>-11 [-15, -7]</td>
</tr>
<tr>
<td>Difference to placebo LSM (95% CL)</td>
<td>-18 [-24, -13]</td>
<td>-12 [-17, -6]</td>
<td></td>
</tr>
<tr>
<td><strong>LPS (latency to persistent sleep, min): Sleep onset, assessed objectively by PSG</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline Mean (SD)</td>
<td>64 (37)</td>
<td>67 (39)</td>
<td>67 (40)</td>
</tr>
<tr>
<td>Month 1 Mean (SD)</td>
<td>34 (27)</td>
<td>38 (32)</td>
<td>46 (36)</td>
</tr>
<tr>
<td>Change from baseline LSM (95% CL)</td>
<td>-31 [-35, -28]</td>
<td>-28 [-32, -25]</td>
<td>-20 [-23, -17]</td>
</tr>
<tr>
<td>Difference to placebo LSM (95% CL)</td>
<td>-11 [-16, -7]</td>
<td>-8 [-13, -4]</td>
<td></td>
</tr>
<tr>
<td>Month 3 Mean (SD)</td>
<td>30 (23)</td>
<td>36 (34)</td>
<td>43 (34)</td>
</tr>
<tr>
<td>Change from baseline LSM (95% CL)</td>
<td>-35 [-38, -31]</td>
<td>-31 [-34, -27]</td>
<td>-23 [-26, -20]</td>
</tr>
<tr>
<td>Difference to placebo LSM (95% CL)</td>
<td>-12 [-16, -7]</td>
<td>-8 [-12, -3]</td>
<td></td>
</tr>
<tr>
<td><strong>sTST (subjective total sleep time, min): patient-reported</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline Mean (SD)</td>
<td>313 (58)</td>
<td>310 (60)</td>
<td>316 (53)</td>
</tr>
<tr>
<td>Month 1 Mean (SD)</td>
<td>358 (74)</td>
<td>345 (66)</td>
<td>338 (65)</td>
</tr>
<tr>
<td>Change from baseline LSM (95% CL)</td>
<td>44 [38, 49]</td>
<td>34 [29, 40]</td>
<td>22 [16, 27]</td>
</tr>
<tr>
<td>Difference to placebo LSM (95% CL)</td>
<td>22 [14, 30]</td>
<td>13 [5, 20]</td>
<td></td>
</tr>
<tr>
<td>Month 3 Mean (SD)</td>
<td>372 (79)</td>
<td>358 (72)</td>
<td>354 (73)</td>
</tr>
<tr>
<td>Change from baseline LSM (95% CL)</td>
<td>58 [51, 64]</td>
<td>48 [41, 54]</td>
<td>38 [31, 44]</td>
</tr>
<tr>
<td>Difference to placebo LSM (95% CL)</td>
<td>20 [11, 29]</td>
<td>10 [1, 19]</td>
<td></td>
</tr>
<tr>
<td>IDSIQ sleepiness domain score (daytime functioning): patient-reported</td>
<td>25 mg</td>
<td>Placebo</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td><strong>Baseline</strong></td>
<td>Mean (SD)</td>
<td>22.5 (7.2)</td>
<td>22.1 (6.9)</td>
</tr>
<tr>
<td><strong>Month 1</strong></td>
<td>Mean (SD)</td>
<td>18.6 (7.8)</td>
<td>19.4 (7.1)</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>LSM (95% CL)</td>
<td>[-3.8, -3.2]</td>
<td>[-2.8, -2.2]</td>
</tr>
<tr>
<td>Difference to placebo</td>
<td>LSM (95% CL)</td>
<td>[-1.8, -1.0]</td>
<td>[-0.8, 0.0]</td>
</tr>
<tr>
<td><strong>Month 3</strong></td>
<td>Mean (SD)</td>
<td>16.5 (8.1)</td>
<td>17.3 (7.6)</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>LSM (95% CL)</td>
<td>[-5.7, -5.0]</td>
<td>[-4.8, -4.1]</td>
</tr>
<tr>
<td>Difference to placebo</td>
<td>LSM (95% CL)</td>
<td>[-1.9, -0.9]</td>
<td>[-1.0, 0.0]</td>
</tr>
</tbody>
</table>

CL = confidence limits; IDSIQ = Insomnia Daytime Symptoms and Impacts Questionnaire; LSM = least squares mean; PSG = polysomnography; SD = standard deviation.

Table 3: Efficacy on sleep variables and daytime functioning – Study 2

<table>
<thead>
<tr>
<th>WASO (wake after sleep onset, min): sleep maintenance, assessed objectively by PSG</th>
<th><strong>25 mg</strong></th>
<th><strong>Placebo</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline</strong></td>
<td>Mean (SD)</td>
<td>106 (49)</td>
</tr>
<tr>
<td><strong>Month 1</strong></td>
<td>Mean (SD)</td>
<td>80 (44)</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>LSM (95% CL)</td>
<td>[-24, -20]</td>
</tr>
<tr>
<td>Difference to placebo</td>
<td>LSM (95% CL)</td>
<td>[-12, -6]</td>
</tr>
<tr>
<td><strong>Month 3</strong></td>
<td>Mean (SD)</td>
<td>80 (49)</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>LSM (95% CL)</td>
<td>[-24, -19]</td>
</tr>
<tr>
<td>Difference to placebo</td>
<td>LSM (95% CL)</td>
<td>[-10, -4]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LPS (latency to persistent sleep, min): sleep onset, assessed objectively by PSG</th>
<th><strong>25 mg</strong></th>
<th><strong>Placebo</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline</strong></td>
<td>Mean (SD)</td>
<td>69 (41)</td>
</tr>
<tr>
<td><strong>Month 1</strong></td>
<td>Mean (SD)</td>
<td>42 (39)</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>LSM (95% CL)</td>
<td>[-26, -22]</td>
</tr>
<tr>
<td>Difference to placebo</td>
<td>LSM (95% CL)</td>
<td>[-6, -1]</td>
</tr>
<tr>
<td><strong>Month 3</strong></td>
<td>Mean (SD)</td>
<td>39 (37)</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>LSM (95% CL)</td>
<td>[-29, -24]</td>
</tr>
<tr>
<td>Difference to placebo</td>
<td>LSM (95% CL)</td>
<td>[-9, -3]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>sTST (subjective total sleep time, min): patient-reported</th>
<th><strong>25 mg</strong></th>
<th><strong>Placebo</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline</strong></td>
<td>Mean (SD)</td>
<td>308 (53)</td>
</tr>
<tr>
<td><strong>Month 1</strong></td>
<td>Mean (SD)</td>
<td>353 (67)</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>LSM (95% CL)</td>
<td>[44, 28]</td>
</tr>
<tr>
<td>Difference to placebo</td>
<td>LSM (95% CL)</td>
<td>[16, 8]</td>
</tr>
<tr>
<td><strong>Month 3</strong></td>
<td>Mean (SD)</td>
<td>365 (70)</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>LSM (95% CL)</td>
<td>[56, 37]</td>
</tr>
</tbody>
</table>
Difference to placebo
LSM (95% CL)
19
[10, 28]

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IDSIQ sleepiness domain score (daytime functioning): patient-reported</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Baseline</strong></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td></td>
<td>22.2 (6.2)</td>
<td>22.6 (5.8)</td>
</tr>
<tr>
<td><strong>Month 1</strong></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td></td>
<td>18.7 (6.5)</td>
<td>19.8 (6.3)</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>LSM (95% CL)</td>
<td>LSM (95% CL)</td>
</tr>
<tr>
<td></td>
<td>[-4.1, -2.9]</td>
<td>[-3.3, -2.2]</td>
</tr>
<tr>
<td>Difference to placebo</td>
<td>LSM (95% CL)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>-0.8</td>
<td>[-1.6, 0.1]</td>
</tr>
<tr>
<td><strong>Month 3</strong></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td></td>
<td>17.0 (7.0)</td>
<td>18.4 (6.6)</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>LSM (95% CL)</td>
<td>LSM (95% CL)</td>
</tr>
<tr>
<td></td>
<td>[-6.0, -4.6]</td>
<td>[-4.7, -3.3]</td>
</tr>
<tr>
<td>Difference to placebo</td>
<td>LSM (95% CL)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>-1.3</td>
<td>[-2.2, -0.3]</td>
</tr>
</tbody>
</table>

CL = confidence limits; IDSIQ = Insomnia Daytime Symptoms and Impacts Questionnaire; LSM = least squares mean; PSG = polysomnography; SD = standard deviation.

**Rebound insomnia**

The potential for rebound insomnia was assessed during the placebo run-out period after 3 months of treatment with daridorexant in Study 1 and Study 2, looking at the change from baseline to the run-out period in LPS, WASO and sTST. At the recommended dose of 50 mg, for all three endpoints, the mean values at run-out were improved compared to baseline (–15, –3 and 43 min for LPS, WASO and sTST, respectively), indicating that no sign of rebound insomnia was observed upon treatment discontinuation.

**Paediatric population**

The European Medicines Agency has deferred the obligation to submit the results of studies with daridorexant in one or more subsets of the paediatric population in insomnia (see section 4.2 for information on paediatric use).

### 5.2 Pharmacokinetic properties

**Absorption**

Daridorexant is rapidly absorbed following oral administration and reaches peak plasma concentrations within 1–2 h. At an oral dose of 100 mg, daridorexant has an absolute bioavailability of 62%.

Daridorexant plasma exposure is dose proportional between 25 and 50 mg.

**Effect of food**

In healthy subjects, food did not affect total exposure. The \( t_{\text{max}} \) of 50 mg daridorexant was delayed by 1.3 h and \( C_{\text{max}} \) decreased by 16% following administration of a high-fat and high-calorie meal.

**Distribution**

Daridorexant has a volume of distribution of 31 L. Daridorexant is extensively bound (99.7%) to plasma proteins, mostly to albumin and to a lower extent to \( \alpha \)-acid glycoprotein. The blood to plasma ratio is 0.64.

**Biotransformation**
Daridorexant undergoes extensive metabolism and is primarily metabolised by CYP3A4 (89%). Other CYP enzymes are not of clinical relevance and individually contribute to less than 3% of metabolic clearance. None of the major human metabolites (M1, M3, and M10) contribute to the pharmacological effect of the medicinal product.

Daridorexant inhibits several CYP enzymes in vitro. The strongest inhibition was seen on CYP3A4 with a $K_i$ of 4.6–4.8 µM (see section 4.5). Inhibition of CYP2C8, CYP2C9, and CYP2C19 was less pronounced, with $IC_{50}$ values in the range of 8.2–19 µM. Daridorexant induces CYP3A4 mRNA expression in human hepatocytes with an $EC_{50}$ of 2.3 µM and, to a lesser extent, CYP2C9 and CYP2B6. Up-regulation of all CYP enzymes is mediated via activation of the PXR receptor with an $EC_{50}$ of 3 µM. Daridorexant does not induce CYP1A2.

Daridorexant inhibits various transporters in vitro and had the strongest inhibitory effect on BCRP with an $IC_{50}$ of 3.0 µM (see section 4.5). Inhibition of other transporters including OATP, OAT3, OCT1, MATE-2K, MATE1, and P-gp/MDR1 was less pronounced, with $IC_{50}$ values ranging from 8.4–71 µM.

**Elimination**

The primary route of excretion is via faeces (approximately 57%), followed by urine (approximately 28%). Only traces of parent compound were found in urine and faeces.

The terminal half-life of daridorexant is approximately 8 hours.

The PK profile of daridorexant following multiple-dose administration showed similar PK parameters to those observed after single-dose administration. No accumulation was observed.

**Pharmacokinetics in special populations**

No clinically significant differences in the PK of daridorexant were detected based on age, sex, race, or body size. Limited PK data are available in patients older than 75 years.

**Hepatic impairment**

Following administration of a single dose of 25 mg daridorexant, subjects with mild hepatic impairment (Child-Pugh score 5–6) had a similar exposure to unbound daridorexant compared to healthy subjects. In subjects with moderate hepatic impairment (Child-Pugh score 7–9), exposure to unbound daridorexant (AUC) and half-life increased by 1.6 times and 2.1 times, respectively, compared to healthy subjects.

Based on these results, a dose adjustment is recommended in patients with moderate hepatic impairment (see section 4.2).

In patients with severe hepatic impairment (Child-Pugh score ≥ 10), daridorexant has not been studied and is not recommended.

**Renal impairment**

Following administration of a single dose of 25 mg, the PK parameters of daridorexant were similar in subjects with severe renal impairment compared to healthy subjects.

Based on these results, daridorexant can be administered to patients with any degree of renal function impairment without the need for dose adjustment.
5.3 Preclinical safety data

Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. Daridorexant also showed no signs indicative of abuse potential or physical dependence.

No adverse effects were observed in repeat-dose toxicity studies in rats and dogs at exposures that are 72 times and 14 times, respectively, the human exposure at the maximum recommended dose of 50 mg/day.

In dogs under positive stimulation at play, episodes of sudden muscle weakness, reminiscent of cataplexy, were observed as exaggerated pharmacological effects of daridorexant from Week 7 onwards and did not occur after treatment cessation. An overall no-observed-effect level was established at exposures that are 45 times (females) and 78 times (males) the human exposure at 50 mg/day for the free fraction.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core

Mannitol (E421)
Microcrystalline cellulose (E460)
Povidone
Crocarmellose sodium
Silicon dioxide
Magnesium stearate

Film coat

Hypromellose (E464)
Microcrystalline cellulose (E460)
Glycerol
Talc (E553)
Titanium dioxide (E171)
Iron oxide yellow (E172; 50 mg tablets)
Iron oxide red (E172; 25 mg and 50 mg tablets)
Iron oxide black (E172; 25 mg and 50 mg tablets)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

30 months.

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

Polyvinyl chloride (PVC) coated with polyvinylidene chloride (PVdC) and laminated with PVC film blister sealed with an aluminium foil blister, packed in a carton box.
Pack size of 10, 20 or 30 film-coated tablets.

Not all pack sizes may be marketed.

6.6 **Special precautions for disposal**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. **MARKETING AUTHORISATION HOLDER**

Idorsia Pharmaceuticals Deutschland GmbH
Marie-Curie-Strasse 8
79539 Lörrach
Germany

8. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/22/1638/001
EU/1/22/1638/002
EU/1/22/1638/003
EU/1/22/1638/004
EU/1/22/1638/005
EU/1/22/1638/006

9. **DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 29 April 2022

10. **DATE OF REVISION OF THE TEXT**

ANNEX II

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Idorsia Pharmaceuticals Deutschland GmbH
Marie-Curie-Strasse 8
79539 Lörrach
Germany

PharmaKorell GmbH
Georges-Koehler-Str. 2
79539 Lörrach
Germany

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

QUVIVIQ 25 mg film-coated tablets
daridorexant

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 25 mg daridorexant (as hydrochloride)

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablet

10 film-coated tablets
20 film-coated tablets
30 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

20
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Idorsia Pharmaceuticals Deutschland GmbH
Marie-Curie-Strasse 8
79539 Lörrach
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/22/1638/001
EU/1/22/1638/005
EU/1/22/1638/002

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

QUVIVIQ 25 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA

PC
SN
NN
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

**BLISTER**

1. **NAME OF THE MEDICINAL PRODUCT**
   
   QUVIVIQ 25 mg tablets
daridorexant

2. **NAME OF THE MARKETING AUTHORISATION HOLDER**
   
   Idorsia

3. **EXPIRY DATE**
   
   EXP

4. **BATCH NUMBER**
   
   Lot

5. **OTHER**
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

#### OUTER CARTON

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>QUVIVIQ 50 mg film-coated tablets</td>
</tr>
<tr>
<td>daridorexant</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. STATEMENT OF ACTIVE SUBSTANCE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Each tablet contains 50 mg daridorexant (as hydrochloride)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. LIST OF EXCIPIENTS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>4. PHARMACEUTICAL FORM AND CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Film-coated tablet</td>
</tr>
<tr>
<td>10 film-coated tablets</td>
</tr>
<tr>
<td>20 film-coated tablets</td>
</tr>
<tr>
<td>30 film-coated tablets</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. METHOD AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
<tr>
<td>Oral use.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the sight and reach of children.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. OTHER SPECIAL WARNING(S), IF NECESSARY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>8. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

| 9. SPECIAL STORAGE CONDITIONS |
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Idorsia Pharmaceuticals Deutschland GmbH
Marie-Curie-Strasse 8
79539 Lörrach
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/22/1638/003
EU/1/22/1638/006
EU/1/22/1638/004

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

QUVIVIQ 50 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA

PC
SN
NN
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

#### BLISTER

1. **NAME OF THE MEDICINAL PRODUCT**
   
   UQUVIVIQ 50 mg tablets  
daridorexant

2. **NAME OF THE MARKETING AUTHORISATION HOLDER**
   
   Idorsia

3. **EXPIRY DATE**
   
   EXP

4. **BATCH NUMBER**
   
   Lot

5. **OTHER**
B. PACKAGE LEAFLET
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What QUVIVIQ is and what it is used for
2. What you need to know before you take QUVIVIQ
3. How to take QUVIVIQ
4. Possible side effects
5. How to store QUVIVIQ
6. Contents of the pack and other information

1. What QUVIVIQ is and what it is used for

QUVIVIQ contains the active substance daridorexant, which belongs to the class of medicines called “orexin receptor antagonists”.

QUVIVIQ is to treat insomnia in adults.

How QUVIVIQ works
Orexin is a substance produced by the brain that helps keep you awake. By blocking the action of orexin, QUVIVIQ enables you to fall asleep faster and stay asleep longer, and improves your ability to function normally during the day.

2. What you need to know before you take QUVIVIQ

Do not take QUVIVIQ
- if you are allergic to daridorexant or any of the other ingredients of this medicine (listed in section 6).
- if you have narcolepsy, a condition that causes you to suddenly and unexpectedly fall asleep at any time.
- if you are taking medicines which may increase the level of QUVIVIQ in your blood such as:
  - oral medicines to treat fungal infections such as ketoconazole, posaconazole, voriconazole, itraconazole.
  - certain medicines to treat bacterial infections such as the antibiotics clarithromycin, josamycin, telithromycin, troleandomycin.
  - certain medicines to treat HIV infection such as ritonavir, elvitegravir, indinavir, saquinavir, telaprevir, danoprevir, lopinavir, nelfinavir, boceprevir.
certain medicines to treat cancer such as ceritinib, idelalisib, ribociclib, tucatinib. Ask your doctor if the medicine you are taking prevents you from taking QUUVIQ.

**Warnings and precautions**

Talk to your doctor or pharmacist before taking QUUVIQ if you:

- have depression or have or ever had suicidal thoughts
- have a psychiatric disorder
- currently take medicinal products that affect your brain such as treatments for anxiety or depression
- have regularly taken drugs (except as medicines) or been addicted to drugs or alcohol
- have liver problems: depending on their severity, QUUVIQ may not be recommended, or a lower dose might be required.
- have breathing difficulties (such as severe obstructive sleep apnoea or severe chronic obstructive pulmonary disease)
- have a history of falling and are older than 65 (because there is generally a higher risk of falling in patients > 65).

Your doctor may want to monitor how the medicine affects you.

Tell your doctor if you get any of the following side effects while taking QUUVIQ:

- sleep paralysis: a temporary inability to move or talk for up to several minutes upon awakening or falling asleep
- hallucinations: seeing or hearing vivid or disturbing things that are not real upon awakening or falling asleep

If you have depression and you experience a worsening or have thoughts of harming yourself, call your doctor straight away.

**Children and adolescents**

This medicine is not for children and adolescents under 18 years of age because QUUVIQ has not been tested in this age group.

**Other medicines and QUUVIQ**

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines because:

- certain antibiotics (erythromycin, ciprofloxacin, clarithromycin, rifampicin), immunosuppressants (cyclosporine), antifungal agents (itraconazole), cancer treatments (ceritinib), or HIV treatments (ritonavir, efavirenz) can increase or decrease the level of QUUVIQ in the blood. Some of these medicines may be contra-indicated with QUUVIQ (see section “Do not take QUUVIQ”). Your doctor will advise you on this.
- certain medicines that work in your brain (e.g., diazepam, alprazolam) could interact with QUUVIQ. Your doctor will advise you on this.
- certain medicines to treat blood coagulation disorder such as dabigatran and warfarin could interact with QUUVIQ, which would require some precaution. Your doctor will advise you on this.
- certain medicines to treat cardiac impairment such as digoxin could interact with QUUVIQ, which would require some precaution. Your doctor will advise you on this.

**QUUVIQ with food, drink and alcohol**

Drinking alcohol with QUUVIQ can increase the risk of impaired balance and coordination.

Avoid grapefruit or grapefruit juice in the evening as they may increase the level of QUUVIQ in the blood.
Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

It is not known if QUVIVIQ can harm your unborn baby.

It is not known if QUVIVIQ passes into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with QUVIVIQ.

It is not known if QUVIVIQ affects human fertility.

Driving and using machines
A period of approximately 9 hours is recommended between taking QUVIVIQ and driving or using machines. Be cautious about driving or using machines in the morning after taking QUVIVIQ. Do not engage in potentially hazardous activities if you are not sure you are fully alert, especially in the first few days of treatment.

QUVIVIQ contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

3. How to take QUVIVIQ

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

How much QUVIVIQ to take
Your doctor will advise you on the dose of QUVIVIQ to take.

The recommended dose is one 50-mg tablet of QUVIVIQ per night.

If you have liver problems or take certain other medicines, your doctor may prescribe you a lower dose of one 25-mg tablet of QUVIVIQ per night.

The treatment duration should be as short as possible. The appropriateness of continued treatment will be assessed within 3 months by your doctor and periodically thereafter.

- Take QUVIVIQ, one time per night, by mouth, in the half hour before going to bed at night.
- You can take QUVIVIQ with or without food, however it may take longer to work if you take it with or right after a large meal.

If you take more QUVIVIQ than you should
If you take more QUVIVIQ than you should, you may experience excessive sleepiness and muscle weakness. Contact your doctor straight away.

If you forget to take QUVIVIQ
If you forget to take QUVIVIQ at bedtime, then you should not take it later during the night, otherwise you may feel drowsy in the morning. Do not take a double dose to make up for a forgotten tablet.

If you stop taking QUVIVIQ
Treatment with QUVIVIQ can be stopped without a need to gradually reduce the dose, and without harmful effects.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:

Common (may affect up to 1 in 10 people):
- headache
- excessive sleepiness
- dizziness
- tiredness
- feeling sick (nausea)

Uncommon (may affect up to 1 in 100 people):
- temporary inability to move or talk (sleep paralysis) for up to several minutes while you are going to sleep or waking up (see section 2).
- seeing or hearing vivid or disturbing things that are not real (hallucinations; see section 2)

Please talk to your doctor if either of these happen to you.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store QUVIVIQ

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer require. These measures will help to protect the environment.

6. Contents of the pack and other information

What QUVIVIQ contains
The active substance is daridorexant.

QUVIVIQ 25 mg film-coated tablets
Each tablet contains daridorexant hydrochloride, equivalent to 25 mg of daridorexant.

QUVIVIQ 50 mg film-coated tablets
Each tablet contains daridorexant hydrochloride, equivalent to 50 mg of daridorexant.

The other ingredients are:
Tablet cores: Mannitol (E421), microcrystalline cellulose (E460), povidone, croscarmellose sodium (see section 2 “QUVIVIQ contains sodium”), silicon dioxide, magnesium stearate.
Film coating: Hypromellose (E464), microcrystalline cellulose (E460), glycerol, talc (E553), titanium dioxide (E171), iron oxide red (E172), iron oxide black (E172), iron oxide yellow (E172; 50 mg tablets only).

**What QUVIVIQ looks like and contents of the pack**

Film-coated tablet (tablet)

**QUVIVIQ 25 mg film-coated tablets**
Light purple, triangular tablet with 25 on one side, and ‘i’ (Idorsia logo) on the other side.

**QUVIVIQ 50 mg film-coated tablets**
Light orange, triangular tablet with 50 on one side, and ‘i’ (Idorsia logo) on the other side.

QUVIVIQ is available in blister packs of 10, 20 or 30 film-coated tablets.

Not all pack sizes may be marketed.

**Marketing Authorisation Holder**
Idorsia Pharmaceuticals Deutschland GmbH
Marie-Curie-Strasse 8
79539 Lörrach
Germany

**Manufacturer**
Idorsia Pharmaceuticals Deutschland GmbH
Marie-Curie-Strasse 8
79539 Lörrach
Germany

PharmaKorell GmbH
Georges-Koehler-Str. 2
79539 Lörrach
Germany

**This leaflet was last revised in**